Chloroethylnitrosourea-induced cell death and genotoxicity: Cell cycle dependence and the role of DNA double-strand breaks, HR and NHEJ

Cell Cycle

Volumn 11, Issue 14, 2012, Pages 2606-2619

  Nikolova, Teodora ^a   Hennekes, Frank ^a   Bhatti, Anita ^a   Kaina, Bernd ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Damage response; DNA double strand breaks; DNA repair; Glioma; Homologous recombination; Melanoma; Nimustine; Nitrosoureas; Nonhomologous end joining; Sensitivity

Indexed keywords

ATM PROTEIN; BRCA2 PROTEIN; HISTONE H2AX; NIMUSTINE; RAD51 PROTEIN; XRCC3 PROTEIN;

APOPTOSIS; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL SURVIVAL; CHROMOSOME ABERRATION; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DNA CROSS LINKING; DNA END JOINING REPAIR; DOUBLE STRANDED DNA BREAK; G2 PHASE CELL CYCLE CHECKPOINT; GENOTOXICITY; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REVIEW;

EID: 84864391539     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20862     Document Type: Review

References (53)

1. Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer 2012; 12:104-20; PMID:22237395.
2. nd, Rich JN, Reardon DA, Desjardins A, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 2009; 115:3501-11; PMID:19514083; http://dx.doi.org/10.1002/cncr.24398.
3. Apisarnthanarax N, Wood GS, Stevens SR, Carlson S, Chan DV, Liu L, et al. Phase I Clinical Trial of O6-Benzylguanine and Topical Carmustine in the Treatment of Cutaneous T-Cell Lymphoma, Mycosis Fungoides Type. Arch Dermatol 2012; PMID:22250189.
4. Chaichana KL, Zaidi H, Pendleton C, McGirt MJ, Grossman R, Weingart JD, et al. The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival. Neurol Res 2011; 33:759-64; PMID:21756557; http://dx.doi.org/10.1179/1743132811Y.0000000006.
5. Gwak HS, Youn SM, Kwon AH, Lee SH, Kim JH, Rhee CH. ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study. J Neurooncol 2005; 75:173-80; PMID:16132508; http://dx.doi.org/10.1007/s11060-005-1858-8.
6. Quéreux G, Dréno B. Fotemustine for the treatment of melanoma. Expert Opin Pharmacother 2011; 12:2891-904; PMID:22077794; http://dx.doi.org/1 0.1517/14656566.2011.633513.
7. Silvani A, Gaviani P, Lamperti E, Botturi A, Ferrari D, Simonetti G, et al. Lecture: fotemustine in brain tumors. Neurol Sci 2011; 32(Suppl 2):S255-7; PMID:21987288; http://dx.doi.org/10.1007/s10072-011-0800-4.
8. Vauleon E, Mesbah H, Gedouin D, Lecouillard I, Louvel G, Hamlat A, et al. Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab. Bull Cancer 2012; 99:121-6; PMID:22257744.
9. Weller M, Müller B, Koch R, Bamberg M, Krauseneck P; Neuro-Oncology Working Group of the German Cancer Society. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 2003; 21:3276-84; PMID:12947063; http://dx.doi.org/10.1200/JCO.2003.03.509.
10. Ludlum DB. DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat Res 1990; 233:117-26; PMID:2233793; http://dx.doi.org/10.1016/0027-5107(90)90156-X.
11. Hayes MT, Bartley J, Parsons PG, Eaglesham GK, Prakash AS. Mechanism of action of fotemustine, a new chloroethylnitrosourea anticancer agent: evidence for the formation of two DNA-reactive intermediates contributing to cytotoxicity. Biochemistry 1997; 36:10646-54; PMID:9271495; http://dx.doi.org/ 10.1021/bi970791q.
12. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 2007; 6:1079-99; PMID:17485253; http://dx.doi.org/10. 1016/j.dnarep.2007.03.008.
13. Preuss I, Thust R, Kaina B. Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs. Int J Cancer 1996; 65:506-12; PMID:8621235; http://dx.doi.org/10.1002/(SICI)1097-0215(19960208)65:4〈506:: AID-IJC19〉3.0.CO;2-7.
14. Tong WP, Kirk MC, Ludlum DB. Formation of the cross-link 1-[N3-deoxycytidyl),2-[N1-deoxyguanosinyl]ethane in DNA treated with N,N′-bis(2-chloroethyl)-N-nitrosourea. Cancer Res 1982; 42:3102-5; PMID:7093954.
15. Akkari YM, Bateman RL, Reifsteck CA, Olson SB, Grompe M. DNA replication is required To elicit cellular responses to psoralen-induced DNA interstrand cross-links. Mol Cell Biol 2000; 20:8283-9; PMID:11027296; http://dx.doi.org/10. 1128/MCB.20.21.8283-8289.2000.
16. Bessho T. Induction of DNA replication-mediated double strand breaks by psoralen DNA interstrand cross-links. J Biol Chem 2003; 278:5250-4; PMID:12473662; http://dx.doi.org/10.1074/jbc.M212323200.
17. Vasquez KM, Legerski RJ. DNA interstrand cross-links: repair, cell signaling and therapeutic implications. Environ Mol Mutagen 2010; 51:491-2; PMID:20577999.
18. Marosi C. Complications of chemotherapy in neurooncology. Handb Clin Neurol 2012; 105:873-85; PMID:22230539; http://dx.doi.org/10.1016/B978-0-444- 53502-3.00029-X.
19. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002; 20:2388-99; PMID:11981013; http://dx.doi.org/10.1200/JCO.2002.06. 110.
20. Kokkinakis DM, Ahmed MM, Chendil D, Moschel RC, Pegg AE. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2′-deoxyguanosine. Clin Cancer Res 2003; 9:3801-7; PMID:14506174.
21. Middleton MR, Margison GP. Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol 2003; 4:37-44; PMID:12517538; http://dx.doi.org/10.1016/S1470-2045(03)00959-8.
22. Rahn JJ, Adair GM, Nairn RS. Multiple roles of ERCC1-XPF in mammalian interstrand cross-link repair. Environ Mol Mutagen 2010; 51:567-81; PMID:20658648.
23. Ho TV, Schärer OD. Translesion DNA synthesis polymerases in DNA interstrand crosslink repair. Environ Mol Mutagen 2010; 51:552-66; PMID:20658647.
24. Hinz JM. Role of homologous recombination in DNA interstrand crosslink repair. Environ Mol Mutagen 2010; 51:582-603; PMID:20658649.
25. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006; 12:440-50; PMID:16899408; http://dx.doi.org/10.1016/j.mol-med.2006.07. 007.
26. Cejka P, Mojas N, Gillet L, Schär P, Jiricny J. Homologous recombination rescues mismatch-repair-dependent cytotoxicity of S(N)1-type methylating agents in S. cerevisiae. Curr Biol 2005; 15:1395-400; PMID:16085492; http://dx.doi.org/10.1016/j.cub.2005.07.032.
27. Quiros S, Roos WP, Kaina B. Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. Cell Cycle 2010; 9:168-78; PMID:20016283; http://dx.doi.org/10.4161/cc.9.1.10363.
28. Roos WP, Nikolova T, Quiros S, Naumann SC, Kiedron O, Zdzienicka MZ, et al. Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair (Amst) 2009; 8:72-86; PMID:18840549; http://dx.doi.org/10.1016/j.dnarep.2008.09.003.
29. Nikolova T, Ensminger M, Löbrich M, Kaina B. Homologous recombination protects mammalian cells from replication-associated DNA double-strand breaks arising in response to methyl methanesulfonate. DNA Repair (Amst) 2010; 9:1050-63; PMID:20708982; http://dx.doi.org/10.1016/j.dnarep.2010. 07.005.
30. Ljungman M. The DNA damage response - repair or despair? Environ Mol Mutagen 2010; 51:879-89; PMID:20818630; http://dx.doi.org/10.1002/em.20597.
31. Shi W, Feng Z, Zhang J, Gonzalez-Suarez I, Vanderwaal RP, Wu X, et al. The role of RPA2 phosphorylation in homologous recombination in response to replication arrest. Carcinogenesis 2010; 31:994-1002; PMID:20130019; http://dx.doi.org/10.1093/carcin/bgq035.
32. Li X, Heyer WD. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res 2008; 18:99-113; PMID:18166982; http://dx.doi.org/10.1038/ cr.2008.1.
33. Nakanishi K, Cavallo F, Perrouault L, Giovannangeli C, Moynahan ME, Barchi M, et al. Homology-directed Fanconi anemia pathway cross-link repair is dependent on DNA replication. Nat Struct Mol Biol 2011; 18:500-3; PMID:21423196; http://dx.doi.org/10.1038/nsmb.2029.
34. Roos WP, Kaina B. DNA damage-induced apoptosis: From specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett 2012; PMID:22261329; http://dx.doi.org/10.1016/j.can-let.2012.01.007.
35. Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 2006; 24:4412-7; PMID:16983109; http://dx.doi.org/10.1200/JCO.2006.06.9104.
36. Kondo N, Takahashi A, Mori E, Noda T, Zdzienicka MZ, Thompson LH, et al. FANCD1/BRCA2 plays predominant role in the repair of DNA damage induced by ACNU or TMZ. PLoS One 2011; 6:e19659; PMID:21573016; http://dx.doi.org/10.1371/ journal.pone.0019659.
37. Quiros S, Roos WP, Kaina B. Rad51 and BRCA2 - New molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS One 2011; 6:e27183; PMID:22073281; http://dx.doi.org/10.1371/journal.pone.0027183.
38. Kondo N, Takahashi A, Mori E, Noda T, Su X, Ohnishi K, et al. DNA ligase IV is a potential molecular target in ACNU sensitivity. Cancer Sci 2010; 101:1881-5; PMID:20487264; http://dx.doi.org/10.1111/j.1349-7006.2010.01591.x.
39. Mochan TA, Venere M, DiTullio RA Jr., Halazonetis TD. 53BP1, an activator of ATM in response to DNA damage. DNA Repair (Amst) 2004; 3:945-52; PMID:15279780; http://dx.doi.org/10.1016/j.dnarep.2004.03.017.
40. Zhou XY, Wang X, Wang H, Chen DJ, Li GC, Iliakis G, et al. Ku affects the ATM-dependent S phase checkpoint following ionizing radiation. Oncogene 2002; 21:6377-81; PMID:12214278; http://dx.doi.org/10.1038/sj.onc.1205782.
41. Wei L, Lan L, Hong Z, Yasui A, Ishioka C, Chiba N. Rapid recruitment of BRCA1 to DNA double-strand breaks is dependent on its association with Ku80. Mol Cell Biol 2008; 28:7380-93; PMID:18936166; http://dx.doi.org/10.1128/MCB.01075- 08.
42. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000; 275:23899-903; PMID:10843985; http://dx.doi.org/10. 1074/jbc.C000276200.
43. Liu Y, Tarsounas M, O'regan P, West SC. Role of RAD51C and XRCC3 in genetic recombination and DNA repair. J Biol Chem 2007; 282:1973-9; PMID:17114795; http://dx.doi.org/10.1074/jbc.M609066200.
44. Batista LF, Roos WP, Christmann M, Menck CF, Kaina B. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res 2007; 67:11886-95; PMID:18089819; http://dx.doi.org/10.1158/0008-5472.CAN-07-2964.
45. Kraakman-van der Zwet M, Overkamp WJ, van Lange RE, Essers J, van Duijn-Goedhart A, Wiggers I, et al. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol Cell Biol 2002; 22:669-79; PMID:11756561; http://dx.doi.org/10.1128/MCB.22. 2.669-679.2002.
46. Hinz JM, Tebbs RS, Wilson PF, Nham PB, Salazar EP, Nagasawa H, et al. Repression of mutagenesis by Rad51D-mediated homologous recombination. Nucleic Acids Res 2006; 34:1358-68; PMID:16522646; http://dx.doi.org/10.1093/nar/gkl020.
47. Errami A, Finnie NJ, Morolli B, Jackson SP, Lohman PH, Zdzienicka MZ. Molecular and biochemical characterization of new X-ray-sensitive hamster cell mutants defective in Ku80. Nucleic Acids Res 1998; 26:4332-8; PMID:9742232; http://dx.doi.org/10.1093/nar/26.19.4332.
48. Singleton BK, Priestley A, Steingrimsdottir H, Gell D, Blunt T, Jackson SP, et al. Molecular and biochemical characterization of xrs mutants defective in Ku80. Mol Cell Biol 1997; 17:1264-73; PMID:9032253.
49. Uematsu N, Weterings E, Yano K, Morotomi-Yano K, Jakob B, Taucher-Scholz G, et al. Autophosphorylation of DNA-PKCS regulates its dynamics at DNA double-strand breaks. J Cell Biol 2007; 177:219-29; PMID:17438073; http://dx.doi.org/10.1083/jcb.200608077.
50. Errami A, He DM, Friedl AA, Overkamp WJ, Morolli B, Hendrickson EA, et al. XR-C1, a new CHO cell mutant which is defective in DNA-PKcs, is impaired in both V(D)J coding and signal joint formation. Nucleic Acids Res 1998; 26:3146-53; PMID:9628911; http://dx.doi.org/10.1093/nar/26.13.3146.
51. Hayashi T, Takao M, Tanaka K, Yasui A. ERCC1 mutations in UV-sensitive Chinese hamster ovary (CHO) cell lines. Mutat Res 1998; 407:269-76; PMID:9653453.
52. Zdzienicka MZ, van der Schans GP, Natarajan AT, Thompson LH, Neuteboom I, Simons JW. A Chinese hamster ovary cell mutant (EM-C11) with sensitivity to simple alkylating agents and a very high level of sister chromatid exchanges. Mutagenesis 1992; 7:265-9; PMID:1518409; http://dx.doi.org/10.1093/mutage/7.4. 265.
53. Preuss I, Haas S, Eichhorn U, Eberhagen I, Kaufmann M, Beck T, et al. Activity of the DNA repair protein O6-methylguanine-DNA methyltransferase in human tumor and corresponding normal tissue. Cancer Detect Prev 1996; 20:130-6; PMID:8706038.